#HedgePapers No. 13 – Hepatitis C and Hedge Fund Profiteers

HEPATITIS C AND HEDGE FUND PROFITEERS Meet The Hedge Fund Managers Cashing In On Predatory Drug Pricing Schemes from Gilead Sciences For millions of Americans infected with Hepatitis C, the inflated prices of new Hepatitis C drugs from Gilead Sciences translate into limited access and prolonged illness. The pharmaceutical giant is charging as much as $1,125 per pill and $94,500 for a course of its lifesaving treatments, forcing health care systems to limit access, robbing patients of a decent quality of life, and forcing many into serious health problems and complications....